353 results about "Tumor chemotherapy" patented technology

The invention discloses application of active ingredients of juncus effuses in the preparation of medicaments for resisting tumors or inhibiting angiogenesis, health-care food or cosmetics. In the invention, the active ingredients of juncus effuses has the activity of inhibiting the tumors and tumor angiogenesis, and the prepared medicaments for inhibiting the tumors and the tumor angiogenesis can be used for treating or preventing malignancy and diseases relevant to the tumor angiogenesis and also can be used for treatment in tumor chemotherapy and / or auxiliary chemotherapy. In the application, the medicinal curative effect and effect mechanism of the active ingredients of juncus effuses are studied and clarified by taking tumor stem cells, tumor cells and tumor neoangiogenesis as targetspots for treating diseases so as to establish a foundation for the research and development of the active ingredients of juncus effuses and the innovative anti-tumor traditional Chinese medicines ofthe active ingredients and provide scientific basis and important information for the Chinese medicinal treatment of the malignancy.

The invention relates to a pH / reduction dual-sensitive multifunctional nano-micelle for tumor chemotherapy and photothermal combined therapy and application of the pH / reduction dual-sensitive multifunctional nano-micelle. The pH / reduction dual-sensitive multifunctional nano-micelle is characterized in that a PCL-acetal-PEG polymer with pH sensitive characteristic, a PCL-ss-PEG-ss-PCL polymer withreduction sensitive characteristic and a phospholipid DSPE-PEG-NH2 with an active group are used as raw materials and are blended to prepare a pH / reduction intelligent responsive polymer nano-micelleas a carrier; a chemotherapeutic drug and a photosensitizer coat a hydrophobic core of the micelle; a casing is made of hydrophilic PEG and has the characteristic of long circulation and space stability; a folic acid targeting group is modified on the surface of the micelle by a covalent bond; the drug loading capacity is 4 to 10 percent, and the mass ratio of the chemotherapeutic drug to the photosensitizer is 0.5 to 2; the particle size is smaller than 200 nm. The pH / reduction dual-sensitive multifunctional nano-micelle disclosed by the invention has the advantages of good dispersity, smallparticle size, better photothermal conversion effect and high drug loading capacity and encapsulation efficiency; the effect of improving tumor suppression by tumor targeted administration, fluorescence imaging of a tumor site, pH / reduction triggered drug release and chemotherapy and photothermal combined therapy can be realized; the pH / reduction dual-sensitive multifunctional nano-micelle has a broad clinical application prospect in combined targeting therapy of tumors.

The invention belongs to the technical field of nano-medicines, and discloses a photosensitive type cell membrane biomimetic targeting nanodrug for tumor combined therapy and a preparation method thereof. According to the nanodrug and the preparation method thereof, a human O-type red blood cell membrane is used as a carrying platform, albumin is used as a drug carrier, DACHPt is used as a chemotherapeutic drug, ICG is used as a photosensitive reagent, RGD is used as a targeting molecule, so that a biomimetic drug carrying system with biomimetic characteristic and high drug loading capacity and capable of being specifically targeted at tumor cells and realizing synergistic anti-tumor sensitization is prepared, the novel biomimetic drug carrying system not only can realize efficient carrying of the drug, but also can effectively prolong the in-vivo circulation time, so that accurate and continuous drug administration at the position of a focus of a tumor is realized, the defect of tumordrug administration can be efficiently overcome through the biomimetic effect of the drug, and a drug carrying and administration and targeted therapy synergistic working mechanism is formed; and thepurpose of tumor chemotherapy and photo-thermal therapy multi-mechanism combined tumor treatment is achieved, and a new idea and platform are provided for tumor treatment.

The invention relates to a polyamine micromolecular compound, comprising the following structures described in the specification, wherein M<x+> is 0, Zn<2+>, Ga<3+>, Gd<3+>, Ca<2+> or other divalent metal ions and trivalent metal ions; S is a reporter group (including a nuclide labeling prothetic group, a paramagnet, a fluorescein or a microvesicle), such as the nuclide labeling prothetic group: -<11>CH3, -CH2CH2<18>F, -CH2CH2(OCH2CH2)2NHCOC6H4<18>F-p or -CH2CH2(OCH2CH2)2NH-CH2CH2<18>F; R is -H, -OCH3, -OCH2CH3 or -Cl; and R1, R2, R3 and R4 are hydrogen, carboxyl, alkane, alkylene or heteroalkyl. The invention further relates to application of the compound in preparing cell death or apoptosis developers of target phosphatidyl serine (PS) and / or apoptotic cell early free Zn<2+>. The compound provided by the invention is a specific multiamine micromolecular developer for target phosphatidyl serine (PS) and / or apoptotic cell early free Zn<2+>, which can be used for monitoring curative effects of PS-related anti-tumor chemotherapy, radiotherapy, biological therapy and the like; the compound can be used for early differential diagnosis of neurodegenerative diseases (senile dementia and Parkinson's disease), cerebral apoplexy, AIDS (Acquired immune deficiency syndrome), thrombus, atheromatous plaque and myocardial infarction; and the compound can also be used for differential diagnosis and curative effect monitoring of other diseases related to PS expression in the cell death or apoptosis process, such as inflammation development and anti-inflammation therapeutic development.

Belonging to the technical field of biomedical polymer materials, the invention discloses a beta-cyclodextrin based amphiphilic pH responsive star polymer and a preparation method thereof, a micelle system based thereon, a composite material and application thereof. The polymer has a structure shown as the formula (1) in the specification, wherein x=3-20, y=2-30, z=5-35, and n=2-10. The polymer can be reduced in situ to obtain nanogold with small particle size and good stability. The invention also provides a micelle system based on the polymer, the micelle system has strengthened entrapment ability to water-insoluble drugs, can efficiently load hydrophobic drugs, gold nanoparticles and other substances, realizes the combination of tumor imaging diagnosis and tumor chemotherapy, and improves the therapeutic efficiency of cancer. And the polymer is easy to control the proportion of each block, and can be applied to preparation of the water-insoluble drug loaded micelle system to satisfy the release requirements of different drugs.

The invention discloses a hyaluronic acid-modified polypyrrole-wrapped medicine-carrying phase-change material photo-thermal treatment agent and a preparation method thereof. The photo-thermal treatment agent is prepared from a medicine-carrying phase-change material core, a polypyrrole shell and hyaluronic acid which is adsorbed on the surface of the polypyrrole shell layer. The photo-thermal treatment agent prepared through the invention has uniform shape and uniform size, is about 233 nm in particle size, and can be targeted to tumor part; meanwhile, the phase-change material core can makea response to temperature change, and presents temperature-sensitive medicament release. The hyaluronic acid-modified polypyrrole-wrapped medicine-carrying phase-change material photo-thermal treatment agent has high photothermal conversion efficiency, a good opto-acoustic developing effect, a targeted tumor chemotherapy-photothermal therapy synergistic effect after the anti-tumor medicament is loaded, is enhanced on the aspect of the tumor treatment effect, and has a good application prospect.

The invention discloses a polyethylene glycol (PEG) dog-source urate oxidase analogue, wherein the dog-source urate oxidase analogue is natural dog-source urate oxidase and chimeric protein and mutant protein containing part of dog-source and human-source urate oxidase amino acid sequences, the average molecular weight of polyethylene glycol is about 1kDa-40kDa, and each urate oxidase monomer is coupled with 2-15 polyethylene glycol molecules in average. According to the method for preparing mammal-source urate oxidase subjected to covalent modification by the polyethylene glycol, the enzyme activity retention rate is higher than 85.0%, and the purification is higher than 95.0%. According to the method, the dog-source urate oxidase analogue subjected to covalent modification by the polyethylene glycol and drug compositions thereof can be used for preventing and / or treating acute hyperuricemia caused by hematologic tumor chemotherapy and hyperuricemia and chronic gout caused by metabolic disorders.

The invention provides a database for guiding individualized medicine taking of a clinical tumor, a constructing method, a searching method and a device thereof. The constructing method of the database comprises the steps of acquiring common data resources of information of a biomarker which is related to tumor chemotherapy, targeted and immunization medicine taking guidance; screening and classifying the common data resources, and obtaining key field and attribute of biomarker information; performing grade classification and dividing on clinical evidence information; establishing a deciphering database structure framework of the biomarker which is related with tumor chemotherapy, targeting and immunization; and recording the information which corresponds with the key field to the corresponding field position of the database structure framework for obtaining the database for guiding individualized medicine taking of the clinical tumor. According to the method, the multi-layer biomarkers which are detected through detecting technology such as high-flux sequencing and immunocytochemistry are comprehensively considered, thereby covering information at aspects of tumor chemotherapy, targeting and immunization medicine taking guidance, and making knowledge resource reserving for clinical medical guidance for individualized medicine taking of the tumor.

The invention discloses phenylpiperazine derivatives and pharmaceutically acceptable salts thereof. The invention is characterized in that: the derivatives have the structure shown as a formula I; and in the formula, R1 refers to -H, -R, -OR, -COOR, halogen or -CN group, R refers to alkyl, the substitution position of R1 on a benzene ring is a para-position, ortho-position or meta-position of piperazine, m is a natural number ranging from 0 to 2, and R2 refers to a substituted or unsubstituted carboxyl group or sulfonic acid group. The phenylpiperazine derivatives and pharmaceutically acceptable salts thereof can be prepared into medicines for inhibiting tumor cell metastasis and tumor angiogenesis, medicines for treating liver cancer, breast cancer, ovarian cancer, gastric cancer, colon cancer, lung cancer or melanoma, tumor chemotherapy medicines and auxiliary medicines in surgical therapy.

The present invention relates to the applications of forsythia ester glycoside in preparing a sensitivity-enhancing and toxicity-reducing medicine in resisting tumor chemotherapy or AIDS. The present invention is a medicinal compound prepared by forsythia ester glycoside and pharmaceutical carrier and / or excipient. The prepared medicinal compound is used for enhancing sensitivity and reducing toxicity in resisting tumor chemotherapy or AIDS, which has the advantages of good curing effect, less side effects and increasing the living quality of patients.

The invention provides a method and a kit for detecting individualized medication related genes in tumor chemotherapy. Compared with the prior art, the method and the kit have the following advantages: 1) the reagent consumables are simple and stable, and expensive reagents, such as fluorescent dyes, special enzymes and the like, are avoided; 2) the reaction can be carried in a micro scale system, thus reducing usage of the sample and the consumables; 3) theoretically, the genes can be recognized as long as one copied amplified DNA fragment is amplified since mass spectrum technology can directly detect the molecular weight (mass-to-charge ratio) of DNA and can directly determine the types of basic groups (i.e., signal conversion in any form is unnecessary), so that the method has high sensitivity; and 4) the mass spectrum technology also is automatic and allows high-throughput detection, so that when the mass spectrum is combined with multi-primer extension technology, several gene loci can be detected in the same reaction system, thereby greatly reducing work load and increasing detection throughput.

The invention discloses a tumor chemotherapy drug susceptibility detection chip and a using method thereof. The tumor chemotherapy drug susceptibility detection chip is formed by sealing a shell with a chip microstructure on the inner surface and a bottom carrier, wherein the chip microstructure comprises a nutrient solution perfusion unit, four cell culture units and a biological glue filling unit. According to the tumor chemotherapy drug susceptibility detection chip, multiple cell ingredients in in-vitro tumor tissue can be integrated on one micro chip for co-culture, biological factors generated by multiple cells can be diffused to the whole micro platform, heterocytotropic cells are ensured not to be contacted mutually, and the in-vivo growth microenvironment of the in-vitro tumor cell can be simulated to the maximum extent.

The invention discloses a tumor cell actively targeted drug delivery system. The drug delivery system comprises the following component contents (by weight): 100-200 parts of bovine serum albumin, 200-400 parts of folic acid, 0.05-0.10 part of 25% glutaral pentanedial, 0.005-0.01 part of alcohol, 5-15 parts of anhydrous dimethyl sulphoxide, 80-100 parts of dicyclohexylcarbodiimide, 70-80 parts of N-hydroxysuccinimide, 0.4-0.6 part of tri-ethylamine, 100-200 parts of anhydrous acetone, 100-200 parts of ether, and 50-100 parts of polybutylene succinate. The drug delivery system comprises preparation steps of activated folate ester, folic acid-bovine serum albumin and colloid suspension. The drug delivery system has low toxicity to normal tissues while killing tumor cells with high-expression of folate receptors; and the folic acid has low immunogenicity, convenient modification and simple storage. The drug delivery system has the advantages of needing short time to reach targets and clearing blood quickly; has obvious advantages in tumor chemotherapy. The invention further discloses a preparation method and application of the tumor cell actively targeted drug delivery system.

The present invention provides a pharmaceutical preparation for tumor chemotherapy and a method for producing the same, the pharmaceutical preparation for tumor chemotherapy comprises cell vesicles derived from apoptotic tumor cells and chemotherapeutic drugs as active ingredients wrapped within the cell vesicles. The chemotherapeutic drugs contained within the pharmaceutical preparation are chemotherapeutic drugs containing active ingredients for the treatment of the tumors from which the cell vesicles are provided. The present invention also provides a method for producing the pharmaceutical preparation for tumor chemotherapy. The technical solutions provided by the present invention can selectively release the chemotherapeutic drugs to the tumor sites and maintain lasting medicinal effect, increasing their killing effects against tumor cells and reducing the toxic side-effect of the chemotherapeutic drugs to normal cells.

The invention relates to a compound fungal polysaccharide preparation having functions of supporting healthy energy, strengthening spleen and stomach and boosting immunity. The preparation is mainly prepared from the following raw materials in percentage by weight: 10-50% of grifola frondosa, 10-50% of hericium erinaceus polysaccharide, 5-35% of ganoderma lucidum polysaccharide and 5-35% of pachymaran. Traditional Chinese medicine holds that supporting healthy energy is to build up healthful vital energy and consolidate essence, namely boosting the immunity, enhancing the disease resistance of a human body, preventing diseases and keeping away from sub-health. The grifola frondosa and the hericium erinaceus polysaccharide medicinal and edible fungal polysaccharides are capable of boosting immunity, protecting gastric mucosa, and improving such adverse reactions of tumor chemotherapy as lack of appetite, emesis, nausea and leucopenia. Traditional Chinese medicine thinks that lucid ganoderma (ganoderma lucidum polysaccharide) and poria cocos (pachymaran) can invigorate qi and strengthen spleen, and calm heart and nerves; modern researches prove that the preparation can boost immunity, resist tumors, assist in cancer therapy, and treat insomnia and dyspepsia. In conclusion, through rational combination of the four fungal polysaccharides, the preparation has clear functions of supporting healthy energy, strengthening spleen and stomach and boosting immunity, and has an obvious healthcare effect on sub-health; meanwhile, the preparation can be used for improving adverse reactions of tumor chemotherapy.

The invention discloses the application of schisandrin B in the preparation of tumor treating drugs, especially in the preparation of tumor cell multidrug resistance reversal agents and tumor chemotherapy drugs. The compound can also be used in combination with other drugs to further improve the reversal effect. Schizandrin B can effectively reverse the multidrug resistance of tumors. The compound acts on P-glycoprotein and can completely inhibit the function of P-glycoprotein, so it has clinical application significance; in addition, Schizandrin B has low toxicity, but It is toxic to certain tumor cells, so Schizandrin B has good application prospects in clinical tumor chemotherapy, especially as a drug for reversing multidrug resistance of tumor cells.

The invention discloses a composition of albiziz durazz extract for inhibiting angiogenesis and preparation and application, belonging to the field of tradition Chinese medicine applied technique. The invention relates to a composition containing albiziz durazz extract, process for preparation and new usage. The invention discovers for the first time that the composition containing albiziz durazz extract can inhibit angiogenesis activity, and thereby the invention can be used for curing and preventing diseases relating to angiogenesis and also can be used for treatment of tumor chemotherapy and / or auxiliary chemotherapy. The composition of albiziz durazz extract of the invention contains one or a plurality of anti-angiogenesis active components. The invention skillfully takes angiogenesis as the target for curing diseases, studies and expounds medicinal curative effect and mechanism of composition containing albiziz durazz extract. The composition containing albiziz durazz extract can be used as drugs, health care products and / or cosmetics and the like.

The invention belongs to the field of medicaments and particularly relates to inoscavin A as a monomeric component in the phellinus as well as a preparation method and an application of the inoscavin A. The preparation method of the inoscavin A comprises the following steps of: (1) grinding the phellinus serving as a herbal medicine, and carrying out reflux extraction by ethanol; (2) extracting the ethanol extract by petroleum ether, and removing the petroleum ether; (3) extracting the extract by methylene dichloride, taking the ethylene dichloride layer, and drying to obtain the methylene dichloride extract; and (4) dissolving the extract into a flowing phase, carrying out high-speed counter-current chromatography, receiving and merging the flows, and recovering the solvent to obtain dried powder. Due to the adoption of the technical scheme, the compound of the inoscavin A as a monomeric component in the phellinus can be prepared in batch. The experiments in vitro prove that the compound has lung cancer tumor cell inhibition activity and liver cancer tumor cell proliferation activity. The experiments in vivo prove that the compound has the efficacy of diminishing inflammation and regulating immunity and can take effect together with the medicament for tumor chemotherapy so that the medicinal effect of the compound in vitro and vivo can be studied further.

The embodiment of the invention provides a case processing method and device, and belongs to the technical field of computers. By receiving medical order execution information used for representing execution conditions of a patient on the basis of medical order information and fed back by a first user terminal, complication occurrence conditions appearing after the patient leaves a hospital can be monitored at any time, the situation that tracking, nursing and treatment seed guidance are conducted in the whole disease course of tumor chemotherapy patients due to lack of special case managers is effectively avoided, and the overall case management effect is further enhanced. Besides, according to symptom information or examination reports sent by the patient, the case managers can effectively guide diseases in a targeted mode, guidance information is sent to the first user terminal, accordingly the patient can be nursed or seek treatment according to the guidance information. The patient can make an appointment and register by inquiring the community hospital nearest to the position where the patient is currently located, and the overall case management effect is further enhanced.

The present invention discloses a traditional Chinese medicine which is used for treating qi-blood deficiency caused by chemotherapy of tumor, and a preparation method thereof. The ingredients of the traditional Chinese medicine have the following weight portions: 20 to 40 portions of radix astragali, 20 to 40 portions of angelica, 10 to 20 portions of codonopsis pilosula, 10 to 20 portions of Chinese wolfberry, 10 to 20 portions of giant knotweed, 10 to 20 portions of herba centellae, 10 to 20 portions of hemlock parsley, 10 to 20 portions of tuckahoe, 10 to 20 portions of cinnamon, 10 to 20 portions of Astraolylis lancea formalyrata, 10 to 20 portions of forsythia, 10 to 20 portions of radix sileris, 10 to 20 portions of prepared radix rehmanniae, 10 to 20 portions of radix-polygoni multiflori, 10 to 20 portions of ass-skin glue, and 10 to 20 portions of licorice. The toxicity test and the clinical test have proven that the medicine has excellent anti-tumor effects, capability of preventing the pains caused by cancer, less toxic side effects, and mild medicinal effects. The preparation method has the advantages of simple operation, reasonable technology, stable and controllable quality, suitability for industrial production, and less loss of medicine ingredients.

The invention discloses application of diosgenin and derivative thereof for preparing tumor chemotherapy sensitization medicines.

One or more embodiments of the invention provide a tumor drug interpretation database and a construction method and device thereof. The data can comprise a plurality of data sections; the plurality ofdata sections are respectively used for storing tumor-related information; and the plurality of data sections are associated with one another through the same key field label or the same key field label combination. A tumor medication interpretation database with interactively associated data sections is established and the database is used for storing gene variation, drugs, tumor targeted therapy, tumor chemotherapy, tumor immunotherapy, tumor prognosis and other information, a user can rapidly and accurately obtain multi-level interpretation of each tumor gene variation by applying the tumor medication interpretation database, and the tumor medication interpretation database can be suitable for tumor accurate therapy.

A sensitizing synergist of chemicotherapeutic medicine for treating tumor is a liposoluble epigallocatechol gallate (C22H35O11-Ro).

The invention relates to an oral spray for controlling nausea and vomit of chemotherapy and radiation therapy, the formula of the oral spray is composed of ingredients with the following parts by weight: 5-50 parts of drug absorption enhancer, 2-20 parts of drug active ingredient and 30-90 parts of buffer, the drug absorption enhancer can be any one or the combination of more of the following ingredients: azone, propylene glycol, polysorbate (Tween), ethylene glycol deoxycholic acid sodium salt, brij, sodium decanoate, lauric acid, stearic acid, sodium lauryl sulphate, stearyl alcohol sodium sulfate, dioctyl succinate sodium sulfonate, oleic acid, GK2, menthol and borneol; the drug active ingredient can be any one combination of the following ingredients: palonosetron hydrochloride, granisetron, ondansetron, azasetron and tropisetron; and the ingredients of the buffer are sodium citrate buffer solution and phosphate buffer solution. The oral spray provides a formulation which is safer, painless and convenient for patients with advanced tumor, elderly and weak patients, children patients and the patients who suffer from the metal illness and do not obey the oral administration or the injection drug administration.

Application of ginsenoside IH901 in preparing angiogenesis inhibitors relates to the application of the ginsenoside IH901 in the medicament field. The invention provides application of ginsenoside IH901 and a precursor thereof in preparing angiogenesis inhibitors. The ginsenoside IH901 is 20-O-beta-D-glucopyranoside-20(S)-protopanoxadiol which can be used for preparing the angiogenesis inhibitors, and the precursor of the ginsenoside IH901 can be used for preparing the angiogenesis inhibitors. The extracted ginsenoside IH901 and the precursor have inhibitory effect on infiltration metastasis and angiogenesis and are used for preparing medicaments for treating diseases related to tumor angiogenesis and other angiogenesis. The ginsenoside IH901 and precursor are prepared into anti-tumor drugs and other drugs for angiogenesis, thus providing a research base for pharmacodynamics and action mechanism and having values of developing the ginsenoside IH901 and the precursor into drugs for tumor chemotherapy and / or auxiliary chemotherapy.

The invention provides the use of honokiol in the preparing process of anti tumor angiopoiesis medicine with a CAS number of 35354-74-6, the molecular weight being 266.33, the honokiol medicine comprises preparation allowed pharmaceutical excipient or carrier. The dosage form can be intestinal tract or non-intestinal tract combination, and the preparation can be made into liquid preparation, granule, tablet, electuary, capsule, drop pill or injection.

The invention relates to granisetron hydrochloride mouth slaking tablet and the formula and preparing process. The process employs rotary oscillating granulator to produce said slaking agent through direct sheeting method after heat extrusion by melting and gradient cooling. When compared with mouth slaking agent produced with normal melting method, the mouth slaking agent in this invention is characterized by faster slaking speed, higher dissolution rate, intact tablet outlook, stronger rigidity and good taste. If compared with current freeze drying, vacuum drying, spray drying technique, the invention is characterized in that it needs no special production device and condition, no special package, the production process is simple, quality is stable and suitable for industrial production. It provides new products for patients that is dysphagia and bedridden, for old people and children, especially for patients suffering tumor chemotherapy and radiotheraphy.

The present invention belongs to field of pharmaceutical preparation, and relates to an anti-cancer medicine liposome preparation which is sensitive to beam. According to the invention, the liposome preparation is prepared through enveloping the active compound comprising the anti-cancer medicine with lipid. The medicine is released under the function of beam. The preparation can concentrate the tumor chemotherapy and radio-therapeutic sensitivity intensifier which have radio-therapeutic sensitivity intensifying effect to the tumor position, and releases the tumor chemotherapy and radio-therapeutic sensitivity intensifier from the liposome for exerting the curative effect. The preparation increases the effective concentration of tumor chemotherapy and radio-therapeutic sensitivity intensifier which have radio-therapeutic sensitivity intensifying effect at the focus position and the staying time in vivo and the efficiency of entering the infected cell, thereby increasing the anti-tumor effect of medicine, reducing the medicine taking dose and medicine toxicity and prolonging the life duration of tumor patient. The preparation of the invention can be used for treating various tumors.

The invention discloses an enhancement tumor cell medicament screening method and its application mainly for effectively overcoming the multidrug resistance to improve the anti-cancer drug treatment effect in a tumor chemotherapy process. The invention screens an inhibitor which can effectively inhibiting the induction action through luciferase activity detection by using an Nrf2 as a cell drug screen platform of a molecular target and a tBHQ as an Nrf2 inducer, and the inhibitor is a medicament of the enhancement tumor cell. The medicament obtained by the screen is a small molecular compound ZDAK02 (coralyne sulfoacetate coralyne thioacetate). The combined use of the medicament of the invention with the anti-cancer drug Chlorambucil or anti-cancer drug oxaliplatin can enhance the toxicity of the anti-cancer drug to the cancer cells and be helpful for easing even reversing the multidrug resistance to the anti-cancer drugs.